Why Generix (GNBT), Valeant (VRX) And Orexigen (OREX) Looking Good
By Liisa Vexler
In the latest trade session, Generex Biotechnology Corporation (OTCMKTS:GNBT) hit an intraday high level of $0.04. A recent release from GNTB shows that results of an interim analysis study of a vaccine designed to prevent a relapse in breast cancer patients has been reinforced by a Phase II study. The interim analysis took place in October 2011. In the last month, GNTB shares have decreased in value by 26.9%, compared with an increase of 32.04% in the three months prior. The market capitalization figure is $23.24M.
Valeant Pharmaceuticals Intl. Inc. (NYSE:VRX), formerly Biovail Corporation, hit an intraday high level of $150.17. The close of trading result was $146.34. VRX is a multinational pharmaceutical company that specializes in the development and manufacturing of a range of pharmaceutical products. Shares in the company have increased by 10.76% in the last month and 33.99% in the three months prior. The market capitalization figure for the company is $2.91M.
In the latest trading session, Orexigen Therapeutics, Inc. (NASDAQ:OREX) closed the day at $7.38, with an increase of 2.50%.The European EMA has commented favorably about OREX’s anti-obesity drug, Contrave. The firm announced that the product is being reviewed in both the United States and Europe. OREX has a market capitalization value of $748.14M. The corporation has a PEG ratio of -0.62% (expected over a 5 year period) with an in-excess price over sales value of $638.97M. A total debt of $0.00 for the last quarter can be compared with a total cash value of $82.82M for the corporation. This results in a ratio of 4.05% for the most recent quarter.